TrialFrontiers in immunology2026

CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial.

Jingwen Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.